Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Capital Economics: BOJ's Three Dissenting Votes Create Largest Divide Since 2016, Maintains June Rate Hike Forecast

Capital Economics: BOJ's Three Dissenting Votes Create Largest Divide Since 2016, Maintains June Rate Hike Forecast

CointimeCointime2026/04/28 04:49

On April 28, Marcel Thieliant, Head of Asia Economics at Capital Economics, stated that although the Bank of Japan kept interest rates unchanged, its outlook report leaned hawkish. Thieliant continues to hold his prediction that the BOJ will raise rates in June. He added that three members voted in favor of a rate hike, marking the largest dissent since the implementation of negative interest rate policy in 2016. While it was not surprising that hawkish members Takeda and Tamura voted against, it was notable that Nakagawa joined the dissenting camp for the first time.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.

Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.

华尔街见闻•2026/10/26 05:56
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.

A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

智通财经•2026/10/26 04:20
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.